சுகாதாரம் அலகு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுகாதாரம் அலகு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுகாதாரம் அலகு Today - Breaking & Trending Today

Studies evaluate the impact of mobility restrictions during lockdown on air quality in urban areas


Studies evaluate the impact of mobility restrictions during lockdown on air quality in urban areas
Two studies led by María Morales Suárez Varela, group leader of the CIBERESP at the University of Valencia and professor of the Department of Preventive Medicine and Public Health at the academic institution, have evaluated the impact of mobility restrictions on air quality and polluting emissions, in Valencia and in three Italian cities. The lockdown measures improved air quality in urban areas, but not as much as expected given the alleged contribution of traffic to ambient air pollution , explains the researcher.
The restrictive mobility measures to limit the spread of COVID-19 provided a unique opportunity to improve our understanding of the impact of mobility on air pollution in urban areas. ....

Scuola Normale Superiore , Morales Su , Emily Henderson , Public Health , International Journal Of Environmental Research , Centre Of Val , University Of Florence , Department Of Preventive Medicine , University Of Valencia , Preventive Medicine , International Journal , Environmental Research , Avenida De Francia , Pista De Silla , Hygiene Unit , எமிலி ஹென்டர்சன் , பொது ஆரோக்கியம் , சர்வதேச இதழ் ஆஃப் சுற்றுச்சூழல் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் புளோரன்ஸ் , துறை ஆஃப் ப்ரெவெஂடிவ் மருந்து , பல்கலைக்கழகம் ஆஃப் வலென்சியா , ப்ரெவெஂடிவ் மருந்து , சர்வதேச இதழ் , சுற்றுச்சூழல் ஆராய்ச்சி , சுகாதாரம் அலகு ,

Trial to assess antimicrobial nasal spray in treating mild COVID-19


Trial to assess antimicrobial nasal spray in treating mild COVID-19
4
The study will assess whether APR-AOS2020 can reduce the viral load of recently infected COVID-19 patients with mild symptoms.
Investigators have initiated a study to evaluate the efficacy of APR-AOS2020, a novel nasal spray, in the treatment of COVID-19 patients showing mild symptoms.
The study, co-ordinated by lead investigator Professor Giancarlo Icardi, will enrol 57 COVID-19 patients at the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa, Italy. The trial will asses the efficacy and safety of the spray product in reducing viral load in the upper respiratory airways in recently infected individuals. According to APR Applied Pharma Research, who developed APR- AOS2020, when the results are available, they could be the staring point for using the therapeutic in the prevention of more severe symptoms, as well as reducing the risk of infection and spread of virus. ....

United States , Giancarlo Icardi , Pharma Research , Professor Giancarlo Icardi , Hygiene Unit , San Martino Hospital , Antiviral Research , Utah State University , Professor Icardi , ஒன்றுபட்டது மாநிலங்களில் , பார்மா ஆராய்ச்சி , சுகாதாரம் அலகு , சான் மார்டினோ மருத்துவமனை , உட்டா நிலை பல்கலைக்கழகம் ,

Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19


Share this article
Product recently cleared in EU as Class III medical device
BALERNA, Switzerland, May 12, 2021 /PRNewswire/ APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutical drug delivery technologies and systems and innovative products derived thereof, today announced the start of a pivotal clinical trial to assess the efficacy of its product temporarily codenamed APR-AOS2020, a Class III medical device, in the treatment of COVID-19 patients showing mild symptoms. The study is being conducted by the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa, Italy and coordinated by Prof. Giancarlo Icardi as lead investigator. The study is planned to enroll a total of 57 COVID-19 patients who show mild symptoms of the disease and is evaluating the efficacy and safety of the spray product in reducing viral load in the upper respiratory airways in recently infected individuals. Results, when available, could represent the startin ....

United States , Switzerland General , Paolo Galfetti , Professorgiancarlo Icardi , Giancarlo Icardi , Pharma Research , Hygiene Unit , San Martino Hospital , Antiviral Research , Utah State University , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , பார்மா ஆராய்ச்சி , சுகாதாரம் அலகு , சான் மார்டினோ மருத்துவமனை , உட்டா நிலை பல்கலைக்கழகம் ,

Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19


Share this article
Share this article
BALERNA, Switzerland, May 12, 2021 /PRNewswire/ APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutical drug delivery technologies and systems and innovative products derived thereof, today announced the start of a pivotal clinical trial to assess the efficacy of its product temporarily codenamed APR-AOS2020, a Class III medical device, in the treatment of COVID-19 patients showing mild symptoms. The study is being conducted by the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa, Italy and coordinated by Prof. Giancarlo Icardi as lead investigator. The study is planned to enroll a total of 57 COVID-19 patients who show mild symptoms of the disease and is evaluating the efficacy and safety of the spray product in reducing viral load in the upper respiratory airways in recently infected individuals. Results, when available, could represent the starting point for the use of the product in th ....

United States , Switzerland General , Paolo Galfetti , Professorgiancarlo Icardi , Giancarlo Icardi , Pharma Research , Hygiene Unit , San Martino Hospital , Antiviral Research , Utah State University , Apr Applied Pharma Research Sa , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , பார்மா ஆராய்ச்சி , சுகாதாரம் அலகு , சான் மார்டினோ மருத்துவமனை , உட்டா நிலை பல்கலைக்கழகம் ,

Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 [...]


12 maggio 2021 16:52
Fonte: Adnkronos
#salute-e-benessere
Product recently cleared in EU as Class III medical device
BALERNA, Switzerland, May 12, 2021 /PRNewswire/ APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutical drug delivery technologies and systems and innovative products derived thereof, today announced the start of a pivotal clinical trial to assess the efficacy of its product temporarily codenamed APR-AOS2020, a Class III medical device, in the treatment of COVID-19 patients showing mild symptoms. The study is being conducted by the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa, Italy and coordinated by Prof. Giancarlo Icardi as lead investigator. The study is planned to enroll a total of 57 COVID-19 patients who show mild symptoms of the disease and is evaluating the efficacy and safety of the spray product in reducing viral load in the upper respiratory airways in recently infected individuals. Resul ....

United States , Switzerland General , Paolo Galfetti , Professorgiancarlo Icardi , Giancarlo Icardi , Pharma Research , Hygiene Unit , San Martino Hospital , Antiviral Research , Utah State University , Apr Aos2020 , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , பார்மா ஆராய்ச்சி , சுகாதாரம் அலகு , சான் மார்டினோ மருத்துவமனை , உட்டா நிலை பல்கலைக்கழகம் ,